Literature DB >> 24871341

Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.

Mohamed Elmeliegy1, Philip Lowe, Wojciech Krzyzanski.   

Abstract

Monoclonal antibodies (mAbs) exhibit biexponential profiles in plasma that are commonly described with a standard two-compartment model with elimination from the central compartment. These models adequately describe mAb plasma PK. However, these models ignore elimination from the peripheral compartment. This may lead to underestimation of the volume of distribution of the peripheral compartment and thus over-predicts concentration in the peripheral compartment. We developed a simple and physiologically relevant model that incorporates information on binding and dissociation rates between mAb and FcRn receptor, mAb uptake, reflection, and catabolic degradation. We employed a previously published PBPK model and, with assumptions regarding rates of processes controlling mAb disposition, reduced the complex PBPK model to a simpler circular model with central, peripheral, and lymph compartments specifying elimination from both central and peripheral. We successfully applied the model to describe the PK of an investigational mAb. Our model presents an improvement over standard two-compartmental models in predicting whole-body average tissue concentrations while adequately describing plasma PK with minimal complexity and physiologically more meaningful parameters.

Mesh:

Substances:

Year:  2014        PMID: 24871341      PMCID: PMC4070266          DOI: 10.1208/s12248-014-9591-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  22 in total

1.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice.

Authors:  F W BRAMBELL; R HALLIDAY; I G MORRIS
Journal:  Proc R Soc Lond B Biol Sci       Date:  1958-07-01

Review 3.  Pharmacokinetic aspects of biotechnology products.

Authors:  Lisa Tang; Adam M Persky; Günther Hochhaus; Bernd Meibohm
Journal:  J Pharm Sci       Date:  2004-09       Impact factor: 3.534

4.  Monoclonal antibody pharmacokinetics and pharmacodynamics.

Authors:  W Wang; E Q Wang; J P Balthasar
Journal:  Clin Pharmacol Ther       Date:  2008-09-10       Impact factor: 6.875

5.  Lumping of whole-body physiologically based pharmacokinetic models.

Authors:  I A Nestorov; L J Aarons; P A Arundel; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

6.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

7.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model.

Authors:  L T Baxter; H Zhu; D G Mackensen; W F Butler; R K Jain
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

Review 8.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

9.  Development and validation of an enzyme linked immunosorbent assay for the quantification of carcinoembryonic antigen in mouse plasma.

Authors:  Shweta R Urva; Victor C Yang; Joseph P Balthasar
Journal:  J Immunoassay Immunochem       Date:  2009

10.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

View more
  5 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

3.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

Review 4.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

5.  Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.

Authors:  Ninad Varkhede; Laird Forrest
Journal:  J Pharm Pharm Sci       Date:  2018       Impact factor: 2.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.